SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000891293-16-000162
Filing Date
2016-05-10
Accepted
2016-05-10 16:36:51
Documents
44
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cti10q03312016.htm 10-Q 758171
2 EXHIBIT 3.5 ex35-articlesofamendment.htm EX-3.5 11406
3 EXHIBIT 31.1 ex311-cti10q03312016.htm EX-31.1 11025
4 EXHIBIT 31.2 ex312-cti10q03312016.htm EX-31.2 12153
5 EXHIBIT 32 ex32-cti10q03312016.htm EX-32 11932
  Complete submission text file 0000891293-16-000162.txt   2666944

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT ctic-20160331.xml EX-101.INS 313095
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20160331.xsd EX-101.SCH 20767
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ctic-20160331_cal.xml EX-101.CAL 55470
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ctic-20160331_def.xml EX-101.DEF 58817
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20160331_lab.xml EX-101.LAB 307927
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20160331_pre.xml EX-101.PRE 165719
Mailing Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: WA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12465 | Film No.: 161636298
SIC: 2834 Pharmaceutical Preparations